Antibody persistence, PRP-specific immune memory, and booster responses in infants immunised with a combination DTPa–HBV–IPV/Hib vaccine
A new single-injection combination vaccine against six diseases has been developed to accommodate the growing number of recommended paediatric vaccines. A pentavalent liquid diphtheria, tetanus, acellular pertussis (3-component), hepatitis B, and inactivated polio (types 1–3) combined vaccine (DTPa–...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2004-11, Vol.23 (1), p.14-20 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 20 |
|---|---|
| container_issue | 1 |
| container_start_page | 14 |
| container_title | Vaccine |
| container_volume | 23 |
| creator | Nolan, T. Altmann, A. Skeljo, M. Streeton, C. Schuerman, L. |
| description | A new single-injection combination vaccine against six diseases has been developed to accommodate the growing number of recommended paediatric vaccines. A pentavalent liquid diphtheria, tetanus, acellular pertussis (3-component), hepatitis B, and inactivated polio (types 1–3) combined vaccine (DTPa–HBV–IPV) is extemporaneously mixed with a lyophilized
Haemophilus influenza type B (Hib) conjugate vaccine (polyribosyl-ribitol phosphate (PRP)–T) and given as a single-injection. A cohort of 368 healthy infants was initially studied to evaluate the immunogenicity and reactogenicity of this hexavalent combination given as a primary course at 2, 4, and 6 months of age. At 15 months of age, from this cohort, 219 children received a booster dose of a licensed DTPa/Hib (PRP–T) vaccine to assess the booster response, while 70 received a challenge dose of unconjugated PRP (PRP) vaccine (to evaluate Hib-specific memory) plus a separate DTPa vaccine. Seven to 10 days following plain PRP challenge, anti-PRP geometric mean antibody concentrations (GMCs) had increased 13-fold to 5.67
μg/ml, and thirty days after conjugated PRP booster vaccination, anti-PRP antibody GMCs increased 102-fold. Both responses are indicative of immune memory. Vaccination was well tolerated following all primary and booster doses, although 10.5% of booster recipients experienced >50-mm local swelling at the site of DTPa vaccination. We conclude that DTPa–HBV–IPV/Hib is safe and immunogenic for primary vaccination, and that Hib-specific memory is induced by primary vaccination. |
| doi_str_mv | 10.1016/j.vaccine.2004.06.017 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67035928</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X04004839</els_id><sourcerecordid>3420620501</sourcerecordid><originalsourceid>FETCH-LOGICAL-c450t-352e6b626d8bf080322ff0b4d308ccc4ac308378e6fe121a695bdc647989750d3</originalsourceid><addsrcrecordid>eNqFkc9q3DAQxk1paTZpH6FFUJpTvBnJlmSfSpr-2UCgS0lDb0KWx1TLWnIkO2VvfYDe-oZ9kmpZQ6CXwKDR4TcfM9-XZa8oLClQcb5Z3mtjrMMlAyiXIJZA5ZNsQStZ5IzT6mm2ACbKvKTw_Sg7jnEDALyg9fPsiHJOawlskf2-cKNtfLsjA4Zo44jO4BlZf13ncUBjO2uI7fvJIemx92F3RrRrSeN9QgMJGAfvIkZiXapOuzEeeBuxJT_t-INoYnzfWKdH6x35cLPWf3_9Wb2_Te_V-vZ8ZRsyn_Iie9bpbcSXcz_Jvn36eHO5yq-_fL66vLjOTclhzAvOUDSCibZqOqigYKzroCnbAipjTKlN-hSyQtEhZVSLmjetEaWsq1pyaIuT7PSgOwR_N2EcVW-jwe1WO_RTVEJCwWtWPQpSyQrBpEzgm__AjZ-CS0eo5HUNvK6qvRw_UCb4GAN2agi212GnKKh9qmqjZivUPlUFQqVU09zrWX1qemwfpuYYE_B2BnQ0etsF7YyND5womSg4T9y7A4fJ3XuLQUVj94m3NqAZVevtI6v8A5glxLg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1559059888</pqid></control><display><type>article</type><title>Antibody persistence, PRP-specific immune memory, and booster responses in infants immunised with a combination DTPa–HBV–IPV/Hib vaccine</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><source>ProQuest Central UK/Ireland</source><creator>Nolan, T. ; Altmann, A. ; Skeljo, M. ; Streeton, C. ; Schuerman, L.</creator><creatorcontrib>Nolan, T. ; Altmann, A. ; Skeljo, M. ; Streeton, C. ; Schuerman, L.</creatorcontrib><description>A new single-injection combination vaccine against six diseases has been developed to accommodate the growing number of recommended paediatric vaccines. A pentavalent liquid diphtheria, tetanus, acellular pertussis (3-component), hepatitis B, and inactivated polio (types 1–3) combined vaccine (DTPa–HBV–IPV) is extemporaneously mixed with a lyophilized
Haemophilus influenza type B (Hib) conjugate vaccine (polyribosyl-ribitol phosphate (PRP)–T) and given as a single-injection. A cohort of 368 healthy infants was initially studied to evaluate the immunogenicity and reactogenicity of this hexavalent combination given as a primary course at 2, 4, and 6 months of age. At 15 months of age, from this cohort, 219 children received a booster dose of a licensed DTPa/Hib (PRP–T) vaccine to assess the booster response, while 70 received a challenge dose of unconjugated PRP (PRP) vaccine (to evaluate Hib-specific memory) plus a separate DTPa vaccine. Seven to 10 days following plain PRP challenge, anti-PRP geometric mean antibody concentrations (GMCs) had increased 13-fold to 5.67
μg/ml, and thirty days after conjugated PRP booster vaccination, anti-PRP antibody GMCs increased 102-fold. Both responses are indicative of immune memory. Vaccination was well tolerated following all primary and booster doses, although 10.5% of booster recipients experienced >50-mm local swelling at the site of DTPa vaccination. We conclude that DTPa–HBV–IPV/Hib is safe and immunogenic for primary vaccination, and that Hib-specific memory is induced by primary vaccination.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2004.06.017</identifier><identifier>PMID: 15519702</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Antibodies, Bacterial - analysis ; Antibodies, Bacterial - biosynthesis ; Antibodies, Viral - analysis ; Antibodies, Viral - biosynthesis ; Antigens ; Applied microbiology ; Babies ; Bacterial diseases ; Biological and medical sciences ; Cohort Studies ; Combination vaccines ; Confidence intervals ; Diphtheria ; Diphtheria-Tetanus-Pertussis Vaccine - administration & dosage ; Diphtheria-Tetanus-Pertussis Vaccine - adverse effects ; Diphtheria-Tetanus-Pertussis Vaccine - immunology ; Ent and stomatologic bacterial diseases ; Fever ; Fundamental and applied biological sciences. Psychology ; Haemophilus influenzae ; Haemophilus influenzae type b ; Haemophilus Vaccines - administration & dosage ; Haemophilus Vaccines - adverse effects ; Haemophilus Vaccines - immunology ; Health facilities ; Hepatitis ; Hepatitis B ; Hepatitis B Vaccines - administration & dosage ; Hepatitis B Vaccines - adverse effects ; Hepatitis B Vaccines - immunology ; Hib immune response ; Human bacterial diseases ; Human viral diseases ; Humans ; Immunization ; Immunization Schedule ; Immunization, Secondary ; Immunogenicity ; Immunologic Memory ; Infant ; Infant, Newborn ; Infants ; Infectious diseases ; Injection ; Laboratories ; Maternal & child health ; Medical sciences ; Microbiology ; Miscellaneous ; Pain ; Pertussis ; Poliomyelitis ; Public health ; Single-Blind Method ; Tetanus ; Tetanus Toxoid - immunology ; Vaccines ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) ; Vaccines, Combined - immunology ; Vaccines, Conjugate ; Viral diseases ; Viral hepatitis ; Virology ; Whooping cough</subject><ispartof>Vaccine, 2004-11, Vol.23 (1), p.14-20</ispartof><rights>2004 Elsevier Ltd</rights><rights>2005 INIST-CNRS</rights><rights>Copyright Elsevier Limited Nov 15, 2004</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c450t-352e6b626d8bf080322ff0b4d308ccc4ac308378e6fe121a695bdc647989750d3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1559059888?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16426355$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15519702$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nolan, T.</creatorcontrib><creatorcontrib>Altmann, A.</creatorcontrib><creatorcontrib>Skeljo, M.</creatorcontrib><creatorcontrib>Streeton, C.</creatorcontrib><creatorcontrib>Schuerman, L.</creatorcontrib><title>Antibody persistence, PRP-specific immune memory, and booster responses in infants immunised with a combination DTPa–HBV–IPV/Hib vaccine</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>A new single-injection combination vaccine against six diseases has been developed to accommodate the growing number of recommended paediatric vaccines. A pentavalent liquid diphtheria, tetanus, acellular pertussis (3-component), hepatitis B, and inactivated polio (types 1–3) combined vaccine (DTPa–HBV–IPV) is extemporaneously mixed with a lyophilized
Haemophilus influenza type B (Hib) conjugate vaccine (polyribosyl-ribitol phosphate (PRP)–T) and given as a single-injection. A cohort of 368 healthy infants was initially studied to evaluate the immunogenicity and reactogenicity of this hexavalent combination given as a primary course at 2, 4, and 6 months of age. At 15 months of age, from this cohort, 219 children received a booster dose of a licensed DTPa/Hib (PRP–T) vaccine to assess the booster response, while 70 received a challenge dose of unconjugated PRP (PRP) vaccine (to evaluate Hib-specific memory) plus a separate DTPa vaccine. Seven to 10 days following plain PRP challenge, anti-PRP geometric mean antibody concentrations (GMCs) had increased 13-fold to 5.67
μg/ml, and thirty days after conjugated PRP booster vaccination, anti-PRP antibody GMCs increased 102-fold. Both responses are indicative of immune memory. Vaccination was well tolerated following all primary and booster doses, although 10.5% of booster recipients experienced >50-mm local swelling at the site of DTPa vaccination. We conclude that DTPa–HBV–IPV/Hib is safe and immunogenic for primary vaccination, and that Hib-specific memory is induced by primary vaccination.</description><subject>Antibodies, Bacterial - analysis</subject><subject>Antibodies, Bacterial - biosynthesis</subject><subject>Antibodies, Viral - analysis</subject><subject>Antibodies, Viral - biosynthesis</subject><subject>Antigens</subject><subject>Applied microbiology</subject><subject>Babies</subject><subject>Bacterial diseases</subject><subject>Biological and medical sciences</subject><subject>Cohort Studies</subject><subject>Combination vaccines</subject><subject>Confidence intervals</subject><subject>Diphtheria</subject><subject>Diphtheria-Tetanus-Pertussis Vaccine - administration & dosage</subject><subject>Diphtheria-Tetanus-Pertussis Vaccine - adverse effects</subject><subject>Diphtheria-Tetanus-Pertussis Vaccine - immunology</subject><subject>Ent and stomatologic bacterial diseases</subject><subject>Fever</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Haemophilus influenzae</subject><subject>Haemophilus influenzae type b</subject><subject>Haemophilus Vaccines - administration & dosage</subject><subject>Haemophilus Vaccines - adverse effects</subject><subject>Haemophilus Vaccines - immunology</subject><subject>Health facilities</subject><subject>Hepatitis</subject><subject>Hepatitis B</subject><subject>Hepatitis B Vaccines - administration & dosage</subject><subject>Hepatitis B Vaccines - adverse effects</subject><subject>Hepatitis B Vaccines - immunology</subject><subject>Hib immune response</subject><subject>Human bacterial diseases</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Immunization</subject><subject>Immunization Schedule</subject><subject>Immunization, Secondary</subject><subject>Immunogenicity</subject><subject>Immunologic Memory</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Infants</subject><subject>Infectious diseases</subject><subject>Injection</subject><subject>Laboratories</subject><subject>Maternal & child health</subject><subject>Medical sciences</subject><subject>Microbiology</subject><subject>Miscellaneous</subject><subject>Pain</subject><subject>Pertussis</subject><subject>Poliomyelitis</subject><subject>Public health</subject><subject>Single-Blind Method</subject><subject>Tetanus</subject><subject>Tetanus Toxoid - immunology</subject><subject>Vaccines</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</subject><subject>Vaccines, Combined - immunology</subject><subject>Vaccines, Conjugate</subject><subject>Viral diseases</subject><subject>Viral hepatitis</subject><subject>Virology</subject><subject>Whooping cough</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkc9q3DAQxk1paTZpH6FFUJpTvBnJlmSfSpr-2UCgS0lDb0KWx1TLWnIkO2VvfYDe-oZ9kmpZQ6CXwKDR4TcfM9-XZa8oLClQcb5Z3mtjrMMlAyiXIJZA5ZNsQStZ5IzT6mm2ACbKvKTw_Sg7jnEDALyg9fPsiHJOawlskf2-cKNtfLsjA4Zo44jO4BlZf13ncUBjO2uI7fvJIemx92F3RrRrSeN9QgMJGAfvIkZiXapOuzEeeBuxJT_t-INoYnzfWKdH6x35cLPWf3_9Wb2_Te_V-vZ8ZRsyn_Iie9bpbcSXcz_Jvn36eHO5yq-_fL66vLjOTclhzAvOUDSCibZqOqigYKzroCnbAipjTKlN-hSyQtEhZVSLmjetEaWsq1pyaIuT7PSgOwR_N2EcVW-jwe1WO_RTVEJCwWtWPQpSyQrBpEzgm__AjZ-CS0eo5HUNvK6qvRw_UCb4GAN2agi212GnKKh9qmqjZivUPlUFQqVU09zrWX1qemwfpuYYE_B2BnQ0etsF7YyND5womSg4T9y7A4fJ3XuLQUVj94m3NqAZVevtI6v8A5glxLg</recordid><startdate>20041115</startdate><enddate>20041115</enddate><creator>Nolan, T.</creator><creator>Altmann, A.</creator><creator>Skeljo, M.</creator><creator>Streeton, C.</creator><creator>Schuerman, L.</creator><general>Elsevier Ltd</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20041115</creationdate><title>Antibody persistence, PRP-specific immune memory, and booster responses in infants immunised with a combination DTPa–HBV–IPV/Hib vaccine</title><author>Nolan, T. ; Altmann, A. ; Skeljo, M. ; Streeton, C. ; Schuerman, L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c450t-352e6b626d8bf080322ff0b4d308ccc4ac308378e6fe121a695bdc647989750d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Antibodies, Bacterial - analysis</topic><topic>Antibodies, Bacterial - biosynthesis</topic><topic>Antibodies, Viral - analysis</topic><topic>Antibodies, Viral - biosynthesis</topic><topic>Antigens</topic><topic>Applied microbiology</topic><topic>Babies</topic><topic>Bacterial diseases</topic><topic>Biological and medical sciences</topic><topic>Cohort Studies</topic><topic>Combination vaccines</topic><topic>Confidence intervals</topic><topic>Diphtheria</topic><topic>Diphtheria-Tetanus-Pertussis Vaccine - administration & dosage</topic><topic>Diphtheria-Tetanus-Pertussis Vaccine - adverse effects</topic><topic>Diphtheria-Tetanus-Pertussis Vaccine - immunology</topic><topic>Ent and stomatologic bacterial diseases</topic><topic>Fever</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Haemophilus influenzae</topic><topic>Haemophilus influenzae type b</topic><topic>Haemophilus Vaccines - administration & dosage</topic><topic>Haemophilus Vaccines - adverse effects</topic><topic>Haemophilus Vaccines - immunology</topic><topic>Health facilities</topic><topic>Hepatitis</topic><topic>Hepatitis B</topic><topic>Hepatitis B Vaccines - administration & dosage</topic><topic>Hepatitis B Vaccines - adverse effects</topic><topic>Hepatitis B Vaccines - immunology</topic><topic>Hib immune response</topic><topic>Human bacterial diseases</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Immunization</topic><topic>Immunization Schedule</topic><topic>Immunization, Secondary</topic><topic>Immunogenicity</topic><topic>Immunologic Memory</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Infants</topic><topic>Infectious diseases</topic><topic>Injection</topic><topic>Laboratories</topic><topic>Maternal & child health</topic><topic>Medical sciences</topic><topic>Microbiology</topic><topic>Miscellaneous</topic><topic>Pain</topic><topic>Pertussis</topic><topic>Poliomyelitis</topic><topic>Public health</topic><topic>Single-Blind Method</topic><topic>Tetanus</topic><topic>Tetanus Toxoid - immunology</topic><topic>Vaccines</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</topic><topic>Vaccines, Combined - immunology</topic><topic>Vaccines, Conjugate</topic><topic>Viral diseases</topic><topic>Viral hepatitis</topic><topic>Virology</topic><topic>Whooping cough</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nolan, T.</creatorcontrib><creatorcontrib>Altmann, A.</creatorcontrib><creatorcontrib>Skeljo, M.</creatorcontrib><creatorcontrib>Streeton, C.</creatorcontrib><creatorcontrib>Schuerman, L.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nolan, T.</au><au>Altmann, A.</au><au>Skeljo, M.</au><au>Streeton, C.</au><au>Schuerman, L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antibody persistence, PRP-specific immune memory, and booster responses in infants immunised with a combination DTPa–HBV–IPV/Hib vaccine</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2004-11-15</date><risdate>2004</risdate><volume>23</volume><issue>1</issue><spage>14</spage><epage>20</epage><pages>14-20</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>A new single-injection combination vaccine against six diseases has been developed to accommodate the growing number of recommended paediatric vaccines. A pentavalent liquid diphtheria, tetanus, acellular pertussis (3-component), hepatitis B, and inactivated polio (types 1–3) combined vaccine (DTPa–HBV–IPV) is extemporaneously mixed with a lyophilized
Haemophilus influenza type B (Hib) conjugate vaccine (polyribosyl-ribitol phosphate (PRP)–T) and given as a single-injection. A cohort of 368 healthy infants was initially studied to evaluate the immunogenicity and reactogenicity of this hexavalent combination given as a primary course at 2, 4, and 6 months of age. At 15 months of age, from this cohort, 219 children received a booster dose of a licensed DTPa/Hib (PRP–T) vaccine to assess the booster response, while 70 received a challenge dose of unconjugated PRP (PRP) vaccine (to evaluate Hib-specific memory) plus a separate DTPa vaccine. Seven to 10 days following plain PRP challenge, anti-PRP geometric mean antibody concentrations (GMCs) had increased 13-fold to 5.67
μg/ml, and thirty days after conjugated PRP booster vaccination, anti-PRP antibody GMCs increased 102-fold. Both responses are indicative of immune memory. Vaccination was well tolerated following all primary and booster doses, although 10.5% of booster recipients experienced >50-mm local swelling at the site of DTPa vaccination. We conclude that DTPa–HBV–IPV/Hib is safe and immunogenic for primary vaccination, and that Hib-specific memory is induced by primary vaccination.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>15519702</pmid><doi>10.1016/j.vaccine.2004.06.017</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2004-11, Vol.23 (1), p.14-20 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67035928 |
| source | MEDLINE; Access via ScienceDirect (Elsevier); ProQuest Central UK/Ireland |
| subjects | Antibodies, Bacterial - analysis Antibodies, Bacterial - biosynthesis Antibodies, Viral - analysis Antibodies, Viral - biosynthesis Antigens Applied microbiology Babies Bacterial diseases Biological and medical sciences Cohort Studies Combination vaccines Confidence intervals Diphtheria Diphtheria-Tetanus-Pertussis Vaccine - administration & dosage Diphtheria-Tetanus-Pertussis Vaccine - adverse effects Diphtheria-Tetanus-Pertussis Vaccine - immunology Ent and stomatologic bacterial diseases Fever Fundamental and applied biological sciences. Psychology Haemophilus influenzae Haemophilus influenzae type b Haemophilus Vaccines - administration & dosage Haemophilus Vaccines - adverse effects Haemophilus Vaccines - immunology Health facilities Hepatitis Hepatitis B Hepatitis B Vaccines - administration & dosage Hepatitis B Vaccines - adverse effects Hepatitis B Vaccines - immunology Hib immune response Human bacterial diseases Human viral diseases Humans Immunization Immunization Schedule Immunization, Secondary Immunogenicity Immunologic Memory Infant Infant, Newborn Infants Infectious diseases Injection Laboratories Maternal & child health Medical sciences Microbiology Miscellaneous Pain Pertussis Poliomyelitis Public health Single-Blind Method Tetanus Tetanus Toxoid - immunology Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Vaccines, Combined - immunology Vaccines, Conjugate Viral diseases Viral hepatitis Virology Whooping cough |
| title | Antibody persistence, PRP-specific immune memory, and booster responses in infants immunised with a combination DTPa–HBV–IPV/Hib vaccine |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T03%3A19%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antibody%20persistence,%20PRP-specific%20immune%20memory,%20and%20booster%20responses%20in%20infants%20immunised%20with%20a%20combination%20DTPa%E2%80%93HBV%E2%80%93IPV/Hib%20vaccine&rft.jtitle=Vaccine&rft.au=Nolan,%20T.&rft.date=2004-11-15&rft.volume=23&rft.issue=1&rft.spage=14&rft.epage=20&rft.pages=14-20&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/j.vaccine.2004.06.017&rft_dat=%3Cproquest_cross%3E3420620501%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1559059888&rft_id=info:pmid/15519702&rft_els_id=S0264410X04004839&rfr_iscdi=true |